912999-77-0

Basic information

• Product Name: 2,3-Bis(bromomethyl)-1,4-difluorobenzene
• Synonyms: 2,3-Bis(bromomethyl)-1,4-difluorobenzene
• CAS NO: 912999-77-0
• Molecular Formula: C₈H₆Br₂F₂
• Molecular Weight: 299.9380464
• Mol File: 912999-77-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 261℃
• Flash Point: 112℃
• Appearance: /
• Density: 1.912
• CAS DataBase Reference: 2,3-Bis(bromomethyl)-1,4-difluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Bis(bromomethyl)-1,4-difluorobenzene(912999-77-0)
• EPA Substance Registry System: 2,3-Bis(bromomethyl)-1,4-difluorobenzene(912999-77-0)

Safety Data

• Hazardous Substances Data: 912999-77-0(Hazardous Substances Data)

Usage

General Description

2,3-Bis(bromomethyl)-1,4-difluorobenzene is a chemical compound with the molecular formula C8H6Br2F2. It is a derivative of benzene with two bromomethyl groups and two fluorine atoms attached to the 1,4 positions. 2,3-Bis(bromomethyl)-1,4-difluorobenzene is commonly used as a building block in organic synthesis for the production of various pharmaceuticals and agrochemicals. It is also utilized in the manufacturing of advanced materials and specialty chemicals. 2,3-Bis(bromomethyl)-1,4-difluorobenzene is a highly reactive and versatile compound that is widely employed in the chemical industry for a diverse range of applications.

Upstream product

• 1736-90-9 1,4-difluoro-2,3-dimethylbenzene 

Downstream Products

• 912999-78-1 4,7-difluoro-2-(toluene-4-sulphonyl)isoindoline 

Relevant articles and documents

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1- 5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase and/or aurora kinase inhibitors.